FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference. The event, hosted by Scripps Health, will take place from February 11–13, 2026, at the Hyatt Regency La Jolla at Aventine in San Diego. The Scripp ...

FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital workflows. Follo ...

FORT MILL, S.C., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a LockeT purchase order from Universitätsklinikum Frankfurt (Frankfurt University Hospital). This purchase order marks the official entry of LockeT into Germany. The purchase order includes the LockeT suture retention device, a state-of-the-art solution ...

Expands Global Footprint to 15 CountriesFORT MILL, S.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a VIVO purchase order from University Clinical Center Ljubljana, a leading hospital in Slovenia. This expands Catheter Precision’s global sales footprint to 15 countries. The University Clinical Center Ljubljana i ...

Company secures first purchase order and multi-year commitment at Ireland’s largest electrophysiology centerFort Mill, SC, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a leader in advanced electrophysiology solutions, today announced the successful implementation of LockeT and the first LockeT purchase order at Mater Private Hospital, located in Dublin, Ireland. This marks a significant milestone in the company’s global expansion strategy and reinforces its commitment ...

Core Insights - Catheter Precision, Inc. has successfully secured a significant tender for its VIVO™ system at Albert Szent-Györgyi Health Centre in Hungary, marking its first installation in the country and reinforcing its growth strategy in Central and Eastern Europe [1][2][3] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [5] Product Details - The VIVO system is a non-invasive 3D imaging technology designed to identify the origin of ventricular arrhythmias prior to procedures, thereby streamlining workflow and reducing procedure time. It has received FDA marketing clearance and holds the CE Mark [4] Market Expansion - The tender at Szeged University Hospital is part of a broader strategy for Catheter Precision to expand into emerging markets, with Hungary identified as a key region for growth. This installation is expected to facilitate wider adoption of the VIVO system throughout Central Europe [2][3]

Core Insights - Catheter Precision, Inc. has successfully launched its LockeT suture retention device in Switzerland, marking a significant milestone for the company in the cardiac electrophysiology market [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, particularly through advancements in electrophysiology procedures [4] Product Launch and Clinical Outcomes - The first clinical cases of the LockeT device were performed at Spitalzentrum Biel, led by PD Dr. Rainer Zbinden, resulting in excellent procedural outcomes and positive feedback from clinical and nursing teams [2] - The LockeT device is designed to assist in wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA, also having received CE Mark approval [3] Strategic Partnerships - The launch follows a strategic distribution agreement with FuMedica AG, a prominent Swiss medical device distributor, which will facilitate the introduction of LockeT to hospitals and clinics across Switzerland, thereby expanding Catheter Precision's European presence [2][3] Market Growth - Over 10,000 LockeT devices have been shipped globally, indicating rapid growth and the company's commitment to working closely with partners to enhance patient care [3]

Core Insights - Catheter Precision, Inc. is positioned to expand the commercialization of its LockeT device following the recent addition of key electrophysiology (EP) ablation procedures to the ambulatory surgery centers (ASC) by the Centers for Medicare and Medicaid Services (CMS) [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for cardiac arrhythmias and advancing electrophysiology procedures through collaboration with physicians [5] Product Information - The LockeT device is a suture retention device designed for wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA and has received CE Mark approval [4] Industry Impact - The addition of EP ablation codes to the ASC-Covered Procedures List (ASC-CPL) by CMS, effective January 1, 2026, significantly enhances Medicare beneficiary access to EP services, marking a major advancement in the delivery of EP care in over two decades [2] Market Opportunity - The new CMS codes will facilitate additional patient scheduling and allow for the use of LockeT in more facilities, supporting physicians and patients in post-ablation recovery while ensuring cost-effectiveness and safety [3]

Core Insights - Catheter Precision, Inc. has achieved rapid commercial uptake of its LockeT closure device in South Africa, indicating strong market demand for its product [1][2]. Group 1: Product Implementation - The LockeT device was successfully implemented in five hospitals within two months, with three hospitals using it daily and two using it routinely [2]. - All five hospitals have placed reorders for the LockeT device through the local distributor, HLC Medical [2]. Group 2: Market Importance - The swift adoption of LockeT highlights its significance in emerging markets, where cost-effectiveness and improved workflow are critical [3]. - LockeT is designed to enhance patient care by enabling rapid hemostasis, which allows for same-day discharge [3]. Group 3: Product Overview - LockeT is a suture retention device intended for wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA, also holding CE Mark approval [4]. Group 4: Company Background - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians to advance its products [5].

Core Insights - Catheter Precision, Inc. has secured its first multi-year agreement in France for the VIVO™ system, marking a significant commitment to the French electrophysiology market [1][4] - The VIVO system will be installed at the Centre Hospitalier Régional Universitaire (CHRU) Nancy, enhancing the hospital's capabilities in complex arrhythmia ablation [1][2] - This follows a successful deployment at CHU Rennes, which was Catheter Precision's largest purchase order in Europe, indicating strong demand and positive early results [3][4] Company Overview - Catheter Precision is a US-based medical device company focused on developing advanced technologies for cardiac electrophysiology [6] - The company aims to improve treatment for cardiac arrhythmias through innovative solutions and collaboration with healthcare professionals [6] Product Details - The VIVO system is a non-invasive 3D imaging technology that helps physicians identify the origins of ventricular arrhythmias before procedures, thereby streamlining workflows and reducing procedure times [5] - VIVO has received marketing clearance from both the U.S. FDA and has the CE Mark, indicating its compliance with regulatory standards [5] Market Position - The installation of VIVO at prestigious hospitals like CHRU Nancy and CHU Rennes reflects the growing momentum and clinical value of the product in the French market [4] - The involvement of leading academic centers is crucial for the early adoption of VIVO among physicians, which is expected to drive long-term usage [4]